Penserra Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-220,858
| Closed | -$280K | – | 1383 |
|
|
2023
Q3 | $280K | Hold |
220,858
| – | – | 0.01% | 659 |
|
|
2023
Q2 | $71K | Buy |
220,858
+1,712
| +0.8% | +$550 | ﹤0.01% | 1002 |
|
|
2023
Q1 | $94K | Buy |
219,146
+3,424
| +2% | +$1.47K | ﹤0.01% | 779 |
|
|
2022
Q4 | $114K | Buy |
215,722
+3,424
| +2% | +$1.81K | ﹤0.01% | 788 |
|
|
2022
Q3 | $155K | Sell |
212,298
-137,038
| -39% | -$100K | ﹤0.01% | 682 |
|
|
2022
Q2 | $398K | Sell |
349,336
-1,818
| -0.5% | -$2.07K | 0.01% | 501 |
|
|
2022
Q1 | $719K | Sell |
351,154
-58,908
| -14% | -$121K | 0.02% | 443 |
|
|
2021
Q4 | $1.18M | Buy |
410,062
+29,364
| +8% | +$84.5K | 0.03% | 414 |
|
|
2021
Q3 | $1.61M | Buy |
380,698
+8,314
| +2% | +$35.2K | 0.03% | 369 |
|
|
2021
Q2 | $1.97M | Buy |
372,384
+15,508
| +4% | +$82K | 0.04% | 340 |
|
|
2021
Q1 | $1.66M | Buy |
356,876
+227,624
| +176% | +$1.06M | 0.03% | 316 |
|
|
2020
Q4 | $425K | Buy |
129,252
+64,250
| +99% | +$211K | 0.01% | 391 |
|
|
2020
Q3 | $214K | Sell |
65,002
-29,960
| -32% | -$98.6K | 0.01% | 430 |
|
|
2020
Q2 | $319K | Buy |
94,962
+7,020
| +8% | +$23.6K | 0.02% | 425 |
|
|
2020
Q1 | $336K | Buy |
87,942
+62,814
| +250% | +$240K | 0.02% | 379 |
|
|
2019
Q4 | $125K | Buy |
25,128
+6,402
| +34% | +$31.8K | 0.01% | 538 |
|
|
2019
Q3 | $141K | Buy |
+18,726
| New | +$141K | 0.01% | 457 |
|